BT-13 is a potent, selective agonist of the glial cell-derived neurotrophic factor (GDNF) receptor RET (acts independently of GDNF ligands), promotes sensory neuron neurite outgrowth in vitro, and alleviates neuropathy in rats happened.
in vitro
BT-13 stimulates phosphorylation of RET, as well as RET-dependent intracellular signaling, but activated neither NGF receptor TrkA nor BDNF receptor TrkB nor intracellular signaling in the absence of RET.
< b>
in vivo
BT-13 (20 and 25mg/kg in rats induced by ligation of left L5 and L6 spinal nerves) has a slight antinociceptive/antihyperalgesic effect and protected DRG neurons in rats with surgery-induced neuropathy.
Animal Model:
Rats induced by ligation of left L5 and L6 spinal nerves.
Dosage:
5-25 mg/kg, dissolved in sesame oil containing 5% DMSO.
Administration:
Subcutaneous injections on post-surgical days 1, 3, 5, 8, 10, and 12.
Result:
20 and 25mg/kg decreased mechanical hypersensitivity and normalized expression of sensory neuron markers in dorsal root ganglia.
